From a human health perspective, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Between 10 and 12 million people are affected by the disease and with no known vaccine, the development of new drugs is urgently required. This volume provides a perspective of current treatments and their challenges as well as discussing emerging strategies and methodologies that will drive new drug development for this 'neglected' disease.